Published in Sci Transl Med on June 30, 2010
Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature (2011) 6.21
Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol (2014) 2.00
Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell (2015) 1.74
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest (2014) 1.58
Clinical imaging in regenerative medicine. Nat Biotechnol (2014) 1.43
Cell therapeutics in Parkinson's disease. Neurotherapeutics (2011) 1.32
Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells (2013) 1.31
Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports (2014) 1.29
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology (2011) 1.21
ES cell-derived renewable and functional midbrain dopaminergic progenitors. Proc Natl Acad Sci U S A (2011) 1.17
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 1.12
Clinical application of stem cell therapy in Parkinson's disease. BMC Med (2012) 1.07
Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model. PLoS One (2011) 1.06
Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep (2014) 1.02
Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease. J Neurol (2011) 1.00
Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet (2014) 1.00
Bringing Neural Cell Therapies to the Clinic: Past and Future Strategies. Mol Ther Methods Clin Dev (2016) 0.97
Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol (2015) 0.97
Multivalent ligands control stem cell behaviour in vitro and in vivo. Nat Nanotechnol (2013) 0.95
Moving stem cells to the clinic: potential and limitations for brain repair. Neuron (2015) 0.94
Focusing brain therapeutic interventions in space and time for Parkinson's disease. Curr Biol (2014) 0.93
Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? BMC Med (2010) 0.91
Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study. J Transl Med (2014) 0.90
Experimental therapies for Parkinson's disease: Why fake it? Nature (2011) 0.88
The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review. Front Integr Neurosci (2011) 0.87
Positron emission tomography neuroimaging in Parkinson's disease. Am J Transl Res (2011) 0.85
Dopaminergic neurons for Parkinson's therapy. Nat Biotechnol (2012) 0.84
Cellular programming and reprogramming: sculpting cell fate for the production of dopamine neurons for cell therapy. Stem Cells Int (2012) 0.83
Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain (2015) 0.83
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Med (2013) 0.82
Directed midbrain and spinal cord neurogenesis from pluripotent stem cells to model development and disease in a dish. Front Neurosci (2014) 0.82
Recent imaging advances in neurology. J Neurol (2015) 0.81
GABAergic neuronal precursor grafting: implications in brain regeneration and plasticity. Neural Plast (2011) 0.81
Meeting the need for regenerative therapies I: target-based incidence and its relationship to U.S. spending, productivity, and innovation. Tissue Eng Part B Rev (2012) 0.80
Synthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychotics. PLoS One (2012) 0.80
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci (2016) 0.80
Development of stem cell-based therapy for Parkinson's disease. Transl Neurodegener (2015) 0.80
Pluripotent stem cells for Parkinson's disease: progress and challenges. Stem Cell Res Ther (2013) 0.80
Dopamine receptor mapping with PET imaging in Parkinson's disease. J Neurol (2014) 0.79
Dopamine cell transplantation in Parkinson's disease: challenge and perspective. Br Med Bull (2011) 0.79
Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease. BMC Med (2011) 0.78
Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. Proc Natl Acad Sci U S A (2013) 0.78
Using stem cells and iPS cells to discover new treatments for Parkinson's disease. Parkinsonism Relat Disord (2012) 0.78
Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease. Parkinsons Dis (2012) 0.78
DREADD Modulation of Transplanted DA Neurons Reveals a Novel Parkinsonian Dyskinesia Mechanism Mediated by the Serotonin 5-HT6 Receptor. Neuron (2016) 0.78
Treatment of Parkinson's disease using cell transplantation. Philos Trans R Soc Lond B Biol Sci (2015) 0.78
Selection Based on FOXA2 Expression Is Not Sufficient to Enrich for Dopamine Neurons From Human Pluripotent Stem Cells. Stem Cells Transl Med (2014) 0.78
Positron emission tomography imaging in neurological disorders. J Neurol (2012) 0.77
Efficient generation of hPSC-derived midbrain dopaminergic neurons in a fully defined, scalable, 3D biomaterial platform. Sci Rep (2017) 0.76
Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum. Basal Ganglia (2012) 0.76
Critical aspects of clinical trial design for novel cell and gene therapies. Parkinsons Dis (2011) 0.76
Differentiation and Characterization of Dopaminergic Neurons From Baboon Induced Pluripotent Stem Cells. Stem Cells Transl Med (2016) 0.75
Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link? Front Cell Neurosci (2016) 0.75
Proceedings: cell therapies for Parkinson's disease from discovery to clinic. Stem Cells Transl Med (2014) 0.75
Replacing Dopamine Neurons in Parkinson's Disease: How did it happen? J Parkinsons Dis (2017) 0.75
What Mechanisms Are Responsible for the Reuptake of Levodopa-Derived Dopamine in Parkinsonian Striatum? Front Neurosci (2016) 0.75
Purification of functional human ES and iPSC-derived midbrain dopaminergic progenitors using LRTM1. Nat Commun (2016) 0.75
The future of stem cells in neurodegenerative disorders of the central nervous system. CMAJ (2011) 0.75
Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challenges. J Neurol Neurosurg Psychiatry (2016) 0.75
BMP2 promotes the differentiation of neural stem cells into dopaminergic neurons in vitro via miR-145-mediated upregulation of Nurr1 expression. Am J Transl Res (2016) 0.75
Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells. Expert Rev Neurother (2015) 0.75
Cell Therapy for Parkinson's Disease. Neurol Med Chir (Tokyo) (2016) 0.75
A PITX3-EGFP Reporter Line Reveals Connectivity of Dopamine and Non-dopamine Neuronal Subtypes in Grafts Generated from Human Embryonic Stem Cells. Stem Cell Reports (2017) 0.75
Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med (2002) 10.10
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A (2003) 5.09
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A (2011) 4.81
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51
Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp (2003) 4.34
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol (2011) 3.42
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cells (2005) 2.88
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol (2012) 2.75
Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke. Nat Neurosci (2009) 2.74
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis (2005) 2.59
Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol (2006) 2.56
Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51
ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord (2010) 2.47
Environment matters: synaptic properties of neurons born in the epileptic adult brain develop to reduce excitability. Neuron (2006) 2.38
Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep (2012) 2.31
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis (2008) 2.27
Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis (2008) 2.26
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain (2004) 2.20
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord (2004) 2.13
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Comparison of accuracy and precision between frame-based and frameless stereotactic navigation for deep brain stimulation electrode implantation. Stereotact Funct Neurosurg (2007) 2.00
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke (2007) 1.98
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord (2008) 1.92
Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci (2006) 1.91
Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord (2009) 1.90
Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. Glia (2009) 1.86
Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol (2006) 1.81
Neurogenesis after ischaemic brain insults. Curr Opin Neurobiol (2003) 1.80
Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol (2008) 1.77
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med (2007) 1.76
Stroke research priorities for the next decade--A representative view of the European scientific community. Cerebrovasc Dis (2006) 1.75
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med (2009) 1.70
Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol Dis (2007) 1.69
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med (2009) 1.65
Multicenter study on deep brain stimulation in Parkinson's disease: an independent assessment of reported adverse events at 4 years. Mov Disord (2008) 1.65
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology (2012) 1.63
The human premotor cortex is 'mirror' only for biological actions. Curr Biol (2004) 1.59
Neurofilament inclusion body disease: a new proteinopathy? Brain (2003) 1.59
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest (2014) 1.58
Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res (2002) 1.55
Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat Neurosci (2012) 1.55
A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One (2013) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases. Mov Disord (2008) 1.53
Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol (2002) 1.51
Is aqueductal stroke volume, measured with cine phase-contrast magnetic resonance imaging scans useful in predicting outcome of shunt surgery in suspected normal pressure hydrocephalus? Neurosurgery (2007) 1.50
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord (2006) 1.49
Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med (2005) 1.49
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol (2010) 1.47
Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord (2010) 1.47
Vascular parkinsonism. J Neurol (2004) 1.46
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain (2008) 1.45
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis (2010) 1.41
The entity of young onset primary cervical dystonia. Mov Disord (2007) 1.41
Parkinson's disease symptoms: the patient's perspective. Mov Disord (2010) 1.40
Stroke-induced neurogenesis in aged brain. Stroke (2005) 1.38
Neural stem and progenitor cells retain their potential for proliferation and differentiation into functional neurons despite lower number in aged brain. J Neurosci (2009) 1.37
Inflammation regulates functional integration of neurons born in adult brain. J Neurosci (2008) 1.35